Literature DB >> 17120616

Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines.

Sarah E Pitfield1, Ianthe Bryant, Desi J Penington, Gar Park, David J Riese.   

Abstract

In many studies, ErbB4 expression in breast tumor samples correlates with a favorable patient prognosis. Similarly, ErbB4 signaling is coupled to cellular differentiation and growth arrest in a variety of model systems. However, in some studies, ErbB4 expression in breast tumor samples correlates with poor outcome. Likewise, studies using some human mammary tumor cell lines suggest that ErbB4 is coupled to malignant phenotypes. Thus, the roles that ErbB4 plays in human breast cancer are still poorly defined. Here we demonstrate that a constitutively active ErbB4 mutant (ErbB4-Q646C) inhibits colony formation on plastic by two human mammary tumor cell lines (SKBR3 and MCF7) and by the MCF10A immortalized human mammary cell line, but does not inhibit colony formation by the MDA-MB-453 and T47D human mammary tumor cell lines. ErbB4 kinase activity is necessary for ErbB4 function and phosphorylation of ErbB4 Tyr1056 is necessary and appears to be sufficient for ErbB4 function. The inhibition of colony formation by MCF10A cells is accompanied by growth arrest but not cell death. These data suggest that ErbB4 behaves as a mammary tumor suppressor and that loss of ErbB4 coupling to growth arrest may be an important event in mammary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17120616      PMCID: PMC2788506          DOI: 10.3727/000000006783981134

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  65 in total

Review 1.  Ligand discrimination by ErbB receptors: differential signaling through differential phosphorylation site usage.

Authors:  C Sweeney; K L Carraway
Journal:  Oncogene       Date:  2000-11-20       Impact factor: 9.867

Review 2.  The Type 1 growth factor receptors and their ligands considered as a complex system.

Authors:  W J Gullick
Journal:  Endocr Relat Cancer       Date:  2001-06       Impact factor: 5.678

Review 3.  Epidermal growth factor receptor signaling.

Authors:  S Bogdan; C Klämbt
Journal:  Curr Biol       Date:  2001-04-17       Impact factor: 10.834

Review 4.  The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.

Authors:  N Prenzel; O M Fischer; S Streit; S Hart; A Ullrich
Journal:  Endocr Relat Cancer       Date:  2001-03       Impact factor: 5.678

5.  EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

Authors:  Zhenhe Suo; Bjørn Risberg; Mats G Kalsson; Kenneth Willman; Anne Tierens; Eva Skovlund; Jahn M Nesland
Journal:  J Pathol       Date:  2002-01       Impact factor: 7.996

6.  Evidence for an alpha-helix --> pi-bulge helicity modulation for the neu/erbB-2 membrane-spanning segment. A 1H NMR and circular dichroism study.

Authors:  M Goetz; C Carlotti; F Bontems; E J Dufourc
Journal:  Biochemistry       Date:  2001-05-29       Impact factor: 3.162

Review 7.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

8.  Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells.

Authors:  C I Sartor; H Zhou; E Kozlowska; K Guttridge; E Kawata; L Caskey; J Harrelson; N Hynes; S Ethier; B Calvo; H S Earp
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

9.  Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.

Authors:  X Chen; T K Yeung; Z Wang
Journal:  Biochem Biophys Res Commun       Date:  2000-11-02       Impact factor: 3.575

10.  gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase.

Authors:  C Y Ni; M P Murphy; T E Golde; G Carpenter
Journal:  Science       Date:  2001-10-25       Impact factor: 47.728

View more
  12 in total

1.  Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines.

Authors:  Richard M Gallo; Ianthe Bryant; Rachael Fry; Eric E Williams; David J Riese
Journal:  Biochem Biophys Res Commun       Date:  2006-08-18       Impact factor: 3.575

2.  The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Authors:  Richard M Gallo; David J Riese
Journal:  Growth Factors       Date:  2007-10       Impact factor: 2.511

3.  The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.

Authors:  Kristy J Wilson; Christopher P Mill; Richard M Gallo; Elizabeth M Cameron; Henry VanBrocklin; Jeffrey Settleman; David J Riese
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

4.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

5.  Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines.

Authors:  Christopher P Mill; Kathleen L Gettinger; David J Riese
Journal:  Exp Cell Res       Date:  2010-11-24       Impact factor: 3.905

Review 6.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

7.  Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant.

Authors:  Thomas Frogne; Rikke V Benjaminsen; Katrine Sonne-Hansen; Boe S Sorensen; Ebba Nexo; Anne-Vibeke Laenkholm; Louise M Rasmussen; David J Riese; Patricia de Cremoux; Jan Stenvang; Anne E Lykkesfeldt
Journal:  Breast Cancer Res Treat       Date:  2008-04-14       Impact factor: 4.872

Review 8.  Functional selectivity of EGF family peptide growth factors: implications for cancer.

Authors:  Kristy J Wilson; Jennifer L Gilmore; John Foley; Mark A Lemmon; David J Riese
Journal:  Pharmacol Ther       Date:  2008-12-16       Impact factor: 12.310

9.  Gene copy numbers of HER family in breast cancer.

Authors:  Anna Zaczek; Marzena Wełnicka-Jaśkiewicz; Krzysztof Piotr Bielawski; Janusz Jaśkiewicz; Andrzej Badzio; Włodzimierz Olszewski; Piotr Rhone; Jacek Jassem
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-28       Impact factor: 4.553

10.  Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.

Authors:  Julie A Przybyla; Juan P Cueva; Benjamin R Chemel; K Joseph Hsu; David J Riese; John D McCorvy; Julia A Chester; David E Nichols; Val J Watts
Journal:  Eur Neuropsychopharmacol       Date:  2008-11-22       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.